Kiyoshi Matsui

Featured in:

Articles

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study

Apr 1, 2023 | rmdopen.bmj.com | Yusuke Miyazaki |Koichi Amano |Kiyoshi Matsui |Satoshi KUBO

Statistical analysisThe data analysis plan is described in the online supplemental information. Briefly, the study was powered to detect a 10% difference in sustained remission rates at week 104 between the tofacitinib and MTX discontinuation groups.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.